Voluntis Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Voluntis group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Voluntis Group Today - Breaking & Trending Today
VOLUNTIS: Voluntis announces its results for the first half of 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
VOLUNTIS: Voluntis announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price of EUR 8.70 per share finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
VOLUNTIS: Voluntis announces the execution of a Share Purchase Agreement between its reference shareholders and Aptar regarding the acquisition of a majority stake in Voluntis at a price of EUR 8.70 per share finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
VOLUNTIS: Voluntis receives CE Mark for new version of Oleena with expanded clinical intelligence New version now authorized for marketing in the United States and the European Union 13 th regulatory clearance (worldwide) obtained by Voluntis for a digital therapeutic Cambridge (USA), Paris (France), May 12, 2021, 8:00 a.m. CET - Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in digital therapeutics, today announced that it has received the CE mark for a new version of Oleena featuring expanded clinical intelligence. Oleena, digital therapeutic for people with cancer Oleena is Voluntis proprietary digital therapeutic that supports patients in the self-management of their symptoms in combination with a wide range of cancer treatments, while allowing healthcare teams to remotely monitor the progress of the disease. It is based on the Theraxium platform developed by Voluntis, which also serves as the foundation for the digital ....
VOLUNTIS: Voluntis, a pioneer-turned-leader in digital therapeutics, sets out its ambitions for profitable growth Cambridge (USA), Paris (France), May 5, 2021, 5:45 p.m. CET - Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in the field of digital therapeutics, today presents a review of its recent years development and reveal its ambitions for the coming years. Pierre Leurent, CEO of Voluntis, said: It has been just over 10 years since we signed our first biopharma licensing agreement providing a pharmaceutical company access to our technological solutions. This decade has allowed us to build a solid foundation for a replicable and value-creating global business model. Just one year ago, we announced our intention to accelerate the commercial momentum on these fundamentals and the inflection is now clear, both in terms of the number of licensing agreements signed and the average size of the partnerships. Our agreement announced a few d ....